{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:44:17Z","timestamp":1792813457700,"version":"4.5.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In 2014, the first patient received a CD22 chimeric antigen receptor (CAR) T-cell product. As one of the earliest approaches targeting an antigen other than CD19, this trial addressed an unmet need while providing insights into CAR T-cell efficacy, impact of manufacturing changes, and management of inflammatory toxicities over its 10-year span. This final chapter provides a comprehensive review of the collective findings. Across 78 patients with B-cell acute lymphoblastic leukemia who received infusion, cytokine release syndrome was observed in 66 (84.6%) patients, whereas 28 (35.9%) had immune effector cell\u2013associated hemophagocytic lymphohistiocytosis\u2013like syndrome (IEC-HS), and 18 (23.1%) had reversible neurotoxicity. Complete response was achieved in 54 (70.1%) patients by day 28, of whom 45 (83.3%) were measurable residual disease negative. Median overall survival was 13.6 months, and median relapse-free survival was 6.1 months. Pharmacokinetics revealed peak CAR T-cell expansion at a median of 14 days (range, 12-50), with no variation by dose. Interestingly, toxicities, CAR T-cell expansion, and disease response did not correlate with baseline disease burden. Additionally, although early intervention approaches to mitigate IEC-HS severity for this construct appeared promising, further study is needed. Given the critical importance of CD22 targeting, this experience serves as a foundation for new approaches targeting CD22 while providing ongoing support for dual-targeting approaches and insights into toxicity mitigation. This trial was registered at www.ClinicalTrials.gov as NCT02315612.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017753","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:30:33Z","timestamp":1766086233000},"page":"1700-1712","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1414-290X","authenticated-orcid":false,"given":"Alexandra","family":"Dreyzin","sequence":"first","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"},{"name":"2Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Yates","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen","family":"Shalabi","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Silbert","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-9253","authenticated-orcid":false,"given":"Hao-Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"3Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-3665","authenticated-orcid":false,"given":"Constance M.","family":"Yuan","sequence":"additional","affiliation":[{"name":"3Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe N.","family":"Hoang","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August A.","family":"Culbert","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Gava","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica S.","family":"Nair","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Giordani","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Little","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Foley","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Nussenblatt","sequence":"additional","affiliation":[{"name":"4Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5226","authenticated-orcid":false,"given":"Terry J.","family":"Fry","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Stroncek","sequence":"additional","affiliation":[{"name":"2Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Highfill","sequence":"additional","affiliation":[{"name":"2Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026030916013867200_bib1","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"issue":"16","key":"2026030916013867200_bib2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2026030916013867200_bib3","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"2","key":"2026030916013867200_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/cancers12020303","article-title":"CD22 expression in B-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults","volume":"12","author":"Lanza","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026030916013867200_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"17","key":"2026030916013867200_bib6","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026030916013867200_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","article-title":"Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J Immunother"},{"issue":"6","key":"2026030916013867200_bib8","doi-asserted-by":"crossref","first-page":"e005898","DOI":"10.1136\/jitc-2022-005898","article-title":"CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity","volume":"11","author":"Jess","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"24","key":"2026030916013867200_bib9","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026030916013867200_bib10","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J Clin Invest"},{"issue":"7","key":"2026030916013867200_bib11","first-page":"438.e1","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"2026030916013867200_bib12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat Med"},{"issue":"10450","key":"2026030916013867200_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"2026030916013867200_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"2026030916013867200_bib15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026030916013867200_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/cpt.2986","article-title":"Best practices and considerations for clinical pharmacology and pharmacometric aspects for optimal development of CAR-T and TCR-T cell therapies: an industry perspective","volume":"114","author":"Mody","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"2026030916013867200_bib17","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.3324\/haematol.2023.284784","article-title":"Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series","volume":"109","author":"Scala","year":"2024","journal-title":"Haematologica"},{"issue":"11","key":"2026030916013867200_bib18","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.2024025910","article-title":"Development of ALL-Hematotox (ALL-HT): predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","volume":"145","author":"Nair","year":"2025","journal-title":"Blood"},{"issue":"9","key":"2026030916013867200_bib19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"2026030916013867200_bib20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","article-title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","volume":"7","author":"Mejstr\u00edkov\u00e1","year":"2017","journal-title":"Blood Cancer J"},{"issue":"9","key":"2026030916013867200_bib21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026030916013867200_bib22","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2026030916013867200_bib23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Protocol AALL1621","volume":"40","author":"O\u2019Brien","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026030916013867200_bib24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"2026030916013867200_bib25","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"2026030916013867200_bib26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results","volume":"38","author":"Schultz","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"2026030916013867200_bib27","doi-asserted-by":"crossref","first-page":"e011549","DOI":"10.1136\/jitc-2025-011549","article-title":"CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy","volume":"13","author":"Myers","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2026030916013867200_bib28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026030916013867200_bib29","doi-asserted-by":"crossref","first-page":"1280580","DOI":"10.3389\/fimmu.2023.1280580","article-title":"Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T cell (tisagenlecleucel) infusion in pediatric and young adult patients with relapse\/refractory acute lymphoblastic leukemia: role of B-cell monitoring","volume":"14","author":"Molinos-Quintana","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"2026030916013867200_bib30","first-page":"73.e1","article-title":"Impact of high-disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel","volume":"28","author":"Ravich","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2026030916013867200_bib31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026030916013867200_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2026030916013867200_bib33","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"2026030916013867200_bib34","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2026030916013867200_bib35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"2026030916013867200_bib36","volume-title":"CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options","year":"2025"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1700\/2506429\/blooda_adv-2025-017753-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1700\/2506429\/blooda_adv-2025-017753-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:01:46Z","timestamp":1773086506000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1700\/557388\/Ten-year-experience-of-CD22-CAR-T-cells-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017753","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,27]]}}}